...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of hematology >Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
【24h】

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

机译：重新挑战仍然是多发性骨髓瘤的抢救治疗选择吗？ 真实寿命硼替佐米的案例重新使用作为复发患者的第二种治疗，将前线暴露于基于Bortezomib的疗法（反弹研究）

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first relapse. This multicenter, observational, retrospective study enrolled 134 MM patients with significant response after bortezomib-based frontline regimens and who had received a first salvage treatment containing bortezomib at relapse. The overall response rate was 71%, including 40% partial responses, 24% very good partial responses, and 7% complete responses. Re-treatment was well-tolerated, with no significant new or unexpected toxicities observed. The median duration of second progression-free survival (PFS) was 15months, while median PFS2 was 55months. With a median follow-up of 56months, overall survival was 94months for the entire series, without significant differences between patients undergoing or not undergoing transplant procedures. This real-life survey indicates that re-treatment including bortezomib as a first salvage therapy could be still considered in MM patients achieving durable response after initial exposure to bortezomib.
机译：鉴于最近有几种新药物和组合的可用性，治疗性重新挑战是多种骨髓瘤（mm）领域的辩论问题。但是，在第一次复发时，博迪西佐马布尔可以获得很少的特定证据。这种多中心，观测性的回顾性研究注册了134毫米患者，基于Bortezomib的前线方案后有重大反应，并在复发时接受了含有硼卓的第一次救生处理。整体反应率为71％，其中包括40％的部分反应，24％非常好的部分反应，以及7％的完全反应。再治疗耐受良好，观察到没有显着的新的或意外毒性。第二进展的生存期（PFS）的中位数是15个月，而中位数PFS2是55个月。随着56个月的中位随访，整个系列的总体存活率为94个月，没有经历或未接受移植程序的患者之间的显着差异。这种现实生活调查表明，在初始暴露于硼佐佐米的患者后，MM患者仍然考虑将包括Bortezomib的重新治疗，包括硼替佐米作为第一次救助治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号